| CARLAT PUBLISHING

Saphris and Fanapt: Two New Antipsychotics

You've probably heard about Fanapt (iloperidone) and Saphris (asenapine), two antipsychotics that have recently won FDA approval for the acute treatment of schizophrenia, and, in the case of Saphris, for the treatment of manic and mixed episodes of bipolar disorder. Are these more “me too”... Read More

“Risk Syndrome for First Psychosis”: A Valid Diagnosis in Psychiatry?

One of the most controversial topics for the DSM-V committee is whether to include a new diagnosis called Risk Syndrome for First Psychosis. Patients with schizophrenia commonly report a history of prodromal symptoms before developing the full-blown disorder... Read More

While we typically pick and choose among various drug classes to treat patients with borderline personality disorder (BPD), we have a hard time basing our choices on the evidence. Read More

Guanfacine, an alpha-2 agonist, is sometimes prescribed off-label for ADHD and has now received official FDA approval in a new, extended-release formulation. Shire will soon market the drug under the brand name Intuniv. So how well does it work? Read More

In order to test whether phone therapy is helpful as an adjunct to antidepressant medication, researchers enrolled 600 depressed outpatients in a randomized trial. Read More

Topics in the Treatment of Schizophrenia

Dr. Ongur, over the past few decades, the dominant theory of schizophrenia has been the dopamine hypothesis, but that has been changing lately. Can give us a quick review of the original hypothesis and then go on to some of the alternative neurochemical theories? Read More